Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraoperative intraperitoneal lavage chemotherapy with lobaplatin for esophagogastric junction adenocarcinoma
ChiCTR2400082841Phase 4Not yet recruiting
- Sponsor
- Cancer Hospital, Chinese Academy of Medical Sciences
- Start
- Apr 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of lobaplatin in gastroesophageal adenocarcinoma (2 arms), sponsored by Cancer Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Incidence of postoperative abdominal metastasis. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
lobaplatin
03
Conditions
gastroesophageal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2400082841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082841.